500 patients66,097 observations150 daysLIVE

Patient P-03322

Synthetic patientONX-7 · Day 142 · 55–64 · M · baseline S10Steering view · 3DOpen companion preview
Is the drug working?

Immune response 62 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 65%, immune response 69 today; biology is not blocking the drug.

Is a side effect starting?

No side effect starting: immune-related gi adverse events 26, immune-related toxicity 21, no drift from the model.

Still taking it?

5 of 5 scheduled doses in the last 60 days are biologically confirmed (100%). Dose signature: resting HR +6 bpm, HRV −9 ms.

last 5 doses · green confirmed · amber logged only · red missed
Plan for this patient
stable, no actionrecommendowner · Companionreview day 149Human Model →
Next action
No action indicated; maintain.
Kept if

Trajectory is stable relative to similar patients; keep the current content.

Daily to-dos in the companion
  • 🍽Keep meals regular; three to four moderate portions spaced through the day
  • 🍽Include a cooked vegetable portion with each main meal
  • Log the daily check-in; one line is enough
  • Keep the current walking rhythm
  • 💊Take the scheduled dose as agreed with your care team
  • 💊No additional supplements this week
Adherence
93% improving

Adherence is not the problem.

Changes the plan if

sleep quality falling under 35 while GI rises

LLIFE OS insight
grounded · add an LLM key for prose

P-03322 is on day 142 of ONX-7 (MR, baseline S10): response improving, tolerance deteriorating, GI favorable. Over 14 days response moved +13 and GI -2; discontinuation risk is 18%. The state is in the restoration basin, heading towards restoration.

Butyrate capacity 54/100, diversity 3.2, normal metabolizer. Pushing it down: Escherichia coli 11.003% (LPS load) (-32.5), Enterobacteriaceae elevated (-14), H2S production above band (-12.5). Pulling it up: Butyrate producers intact (+14.2), Protein (supports) (+6.8). From the daily log: protein -1.6 GI next day, lactose +1.4 GI next day.

No action has been tried yet.

No action is indicated now; the trajectory is stable relative to similar patients.

Therapy response
Improving
Tolerance
Deteriorating
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
18%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (infusion on day 1 of each 14-day cycle)
  1. Day 0 ONX-7 startedBaseline state S10

What changed?

Trajectory is tracking the baseline prediction.

Primary contributors, last 14 days
  • Inflammatory activity-6
  • Toxicity+6
  • Treatment adherence+5
  • GI instability-2
  • Nutritional resilience-2

What helped?

No interventions yet.

    LIFE OS recommendation
    No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Energy level
    Daily log
    5.9/10
    stable · +0.2 vs previous 14 d
    Stress level
    Daily log
    5.1/10
    stable · -0.1 vs previous 14 d
    Pessimism score
    Daily log
    4.1/10
    improving · -0.4 vs previous 14 d
    Sleep quality
    Wearable
    21.1/100
    worsening · -1.1 vs previous 14 d
    Libido
    Daily log
    4/10
    stable · +0.2 vs previous 14 d
    HRV
    Wearable
    21.6 ms
    worsening · -2.2 vs previous 14 d
    Toxicity
    Blood
    21.2/100
    improving · -5.8 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards restoration · 73 from the failing basin, 14 from restoration.

    Would help
    • No untried action with strong evidence. Compose one from primitives.
    • More protein
      GI -1.6 next day on high-intake days · n 18
    Would not help
    • Keep lactose low
      GI +1.4 next day on high-intake days · n 14
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -1.6supporter · 72%
    • Lactose
      +1.4detractor · 60%
    • Histamine load
      -1no signal · 40%
    • Dietary fat load
      +0.9no signal · 36%
    • Caffeine
      -0.9no signal · 35%
    • Alcohol
      -0.5no signal · 17%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    36/100
    vs baseline (day 0)
    -16
    6 improved · 2 worsened
    synthetic signature · consistent with this patient's biology
    • 3 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Streptococcus gallolyticus
    • 2 keystone species absent
    • 4 resistance genes
    Pathogens / opportunists3/5
    Keystone species2/8
    from 3
    Diversity0/2
    from 1
    Metabolic modules1/4
    from 0
    Vitamin synthesis2/7
    Oral translocation1/1
    Host DNA0/1
    Tissue recycling0/1
    from 1
    Central mechanisms0/2
    Virulence factors2/2
    from 3
    Antibiotic resistance genes4/4
    from 5
    Genetic predisposition1/1
    Opportunists above range
    Escherichia coli 11.003% AR
    Klebsiella pneumoniae 3.301% AR
    Streptococcus gallolyticus 1.1% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum
    Capacity
    Shannon 3.2 · butyrate 719 CPM · SCFA 1202
    H2S above band
    2 vitamins below
    Host & mechanisms
    tissue recycling 29/100
    oral translocation 2.53% AR
    4 resistance genes · 2 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 25
      • MicrobiomeF. prausnitzii depleted
    • Autonomic recovery 20
      • WearableShort sleep window
    • Inflammatory signalling 15
      • WearableHRV 22 ms, trending down
    • Mucosal barrier integrity 10
      • WearableSleep 6.1 h, below personal baseline
    DNA
    Fictional pharmacogenomic panel
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3.2 · butyrate capacity 54/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    27 ms
    Sleep
    5.9 h
    Steps
    6,661
    Resting HR
    59 bpm
    Daily log: GI score 26, nutritional resilience 58, adherence 93.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Keep meals regular; three to four moderate portions spaced through the day
    • Include a cooked vegetable portion with each main meal
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Log the daily check-in; one line is enough
    • Keep the current walking rhythm
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • No additional supplements this week
    • Fictional demo item: continue vitamin D as before

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0326435%S17AD-05improved51
    P-0335829%S06AD-05improved51
    P-0302926%S19AD-05no change42
    P-0310840%S01BR-03no change60
    P-0318136%S11BR-03improved65
    P-0322832%S20BR-03no change68
    P-0321329%S16BR-03improved47
    P-0341829%S18BR-03improved40
    P-0346229%S20BR-03improved77
    P-0311728%S10BR-03improved37
    P-0320728%S16CR-01improved72
    P-0300127%S14CR-01improved53